Inhibrx Biosciences (INBX) Retained Earnings: 2023-2025
Historic Retained Earnings for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to -$213.4 million.
- Inhibrx Biosciences' Retained Earnings fell 266.04% to -$213.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.4 million, marking a year-over-year decrease of 266.04%. This contributed to the annual value of -$106.1 million for FY2024, which is 82.71% up from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' Retained Earnings is -$213.4 million, which was down 19.82% from -$178.1 million recorded in Q2 2025.
- In the past 5 years, Inhibrx Biosciences' Retained Earnings registered a high of -$14.4 million during Q2 2024, and its lowest value of -$613.7 million during Q4 2023.
- Its 3-year average for Retained Earnings is -$190.5 million, with a median of -$149.4 million in 2025.
- In the last 5 years, Inhibrx Biosciences' Retained Earnings soared by 82.71% in 2024 and then slumped by 1,136.55% in 2025.
- Inhibrx Biosciences' Retained Earnings (Quarterly) stood at -$613.7 million in 2023, then spiked by 82.71% to -$106.1 million in 2024, then slumped by 266.04% to -$213.4 million in 2025.
- Its Retained Earnings was -$213.4 million in Q3 2025, compared to -$178.1 million in Q2 2025 and -$149.4 million in Q1 2025.